Immsoria Capsule contains Cycloserine 100mg, an antibiotic primarily used in the treatment of tuberculosis, particularly in cases resistant to first-line anti-tubercular drugs. Cycloserine acts by inhibiting bacterial cell wall synthesis through interference with the enzymes involved in peptidoglycan cross-linking, thereby exerting a bacteriostatic effect against Mycobacterium tuberculosis. Immsoria is indicated as part of combination therapy for multidrug-resistant tuberculosis (MDR-TB) and should be administered under strict medical supervision due to its potential neurotoxic side effects. Common adverse reactions include headache, dizziness, tremors, and in some cases, peripheral neuropathy or seizures, necessitating careful dose adjustment and monitoring. It is contraindicated in patients with a history of hypersensitivity to cycloserine or those with severe renal impairment. Caution is advised when prescribing to individuals with a history of psychiatric disorders or epilepsy. Regular monitoring of neurological status and serum drug levels is recommended to minimize toxicity risk. Immsoria Capsule should be taken orally, preferably on an empty stomach to enhance absorption, and adherence to the prescribed regimen is essential for therapeutic efficacy. Patients are advised to report any unusual neurological symptoms promptly to their healthcare provider.